Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Jianang Li

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5070402840. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 13

  1. Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC). First author DOI 10.1016/j.cpt.2024.07.004↗
  2. Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. Co-author DOI 10.1016/j.isci.2024.111693↗
  3. Construction of S100 family members prognosis prediction model and analysis of immune microenvironment landscape at single-cell level in pancreatic adenocarcin… First author DOI 10.1097/js9.0000000000001293↗
  4. NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1. Last author DOI 10.1007/s10620-022-07671-w↗
  5. Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer. Co-author DOI 10.1080/15384101.2021.2014254↗
  6. Upregulated circRNA hsa_circ_0071036 promotes tumourigenesis of pancreatic cancer by sponging miR-489 and predicts unfavorable characteristics and prognosis. Co-author DOI 10.1080/15384101.2021.1874684↗
  7. PRMT1 promotes pancreatic cancer growth and predicts poor prognosis. Co-author DOI 10.1007/s13402-019-00435-1↗
  8. Author Correction: PRMT1 promotes pancreatic cancer growth and predicts poor prognosis. Co-author DOI 10.1007/s13402-019-00480-w↗
  9. HEATR1 Deficiency Promotes Chemoresistance via Upregulating ZNF185 and Downregulating SMAD4 in Pancreatic Cancer. Co-author DOI 10.1155/2020/3181596↗
  10. TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer. Co-author DOI 10.1007/s10238-018-00543-6↗
  11. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Co-author DOI 10.1186/s12967-018-1673-6↗
  12. Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection. Co-author DOI 10.7150/jca.20917↗
  13. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Co-author DOI 10.1097/mpa.0000000000000501↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yefei Rong · 6 shared papers, 2019–2023 · strength 0.82
  2. Tiantao Kuang · 6 shared papers, 2017–2023 · strength 0.75
  3. Wenhui Lou · 5 shared papers, 2019–2025 · strength 0.73
  4. Xu Han · 5 shared papers, 2016–2025 · strength 0.64
  5. Liang Liu · 2 shared papers, 2025 · strength 0.54
  6. Runjie Liu · 2 shared papers, 2025 · strength 0.54
  7. Wenquan Wang · 2 shared papers, 2024–2025 · strength 0.53
  8. Xuefeng Xu · 5 shared papers, 2016–2023 · strength 0.48
  9. Yuan Fang · 4 shared papers, 2019–2021 · strength 0.48
  10. Dansong Wang · 4 shared papers, 2017–2023 · strength 0.42
  11. Huaxiang Xu · 2 shared papers, 2024–2025 · strength 0.41
  12. Yuquan Guo · 2 shared papers, 2024–2025 · strength 0.41
  13. Weilin Mao · 2 shared papers, 2022–2023 · strength 0.38
  14. Wenhui Lou · 3 shared papers, 2016–2023 · strength 0.37
  15. Jinbin Jia · 1 shared paper, 2025 · strength 0.33
  16. Hanlin Yin · 2 shared papers, 2018–2025 · strength 0.28
  17. Ning Pu · 3 shared papers, 2017–2019 · strength 0.22
  18. Wenchuan Wu · 3 shared papers, 2017–2019 · strength 0.22
  19. Mengmeng Liu · 2 shared papers, 2020 · strength 0.22
  20. Haokang Feng · 1 shared paper, 2025 · strength 0.21
  21. Hua Su · 1 shared paper, 2025 · strength 0.21
  22. Lei Zhang · 1 shared paper, 2025 · strength 0.21
  23. Liang Liu · 1 shared paper, 2024 · strength 0.20
  24. Zijin Xu · 1 shared paper, 2024 · strength 0.20
  25. Lei Zhang · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.